Novartis AG (NVS)

Novartis AG operates in the global pharmaceutical industry, focusing on the research, development, manufacturing, and marketing of innovative medicines. The industry is characterized by intense competition, rapid technological change, and extensive government regulation. Key structural forces include the need for significant investment in research and development, the impact of patent expirations and generic competition, and the influence of healthcare cost-containment measures by governments and private payers. The company is a pure-play innovative medicines company following the spin-off of its Sandoz generics and biosimilars business, which was completed on October 4, 2023.

The company's competitive positioning is built on a portfolio of innovative medicines across key therapeutic areas. Primary competitors include other large pharmaceutical and biotechnology companies. Competitive advantages are derived from a strong research and development pipeline, a diversified product portfolio, a global commercial presence, and a focus on high-value therapeutic areas such as oncology, immunology, neuroscience, and cardiovascular, renal and metabolic diseases. The filing does not provide specific market share percentages for the company overall.

Novartis generates revenue primarily through the sale of patented and innovative pharmaceutical products. Revenue is transactional, derived from product sales to wholesale distributors, hospitals, pharmacies, and other healthcare providers. The primary customer segments are patients and healthcare professionals, with the company's commercial operations organized by therapeutic area and geographic region. The company's business model is centered on a research-driven approach to discover and develop new medicines, with a focus on maximizing the value of its key brands and pipeline assets.

The company's operations are organized into several therapeutic areas. The Cardiovascular, Renal and Metabolic segment includes Entresto, which generated net sales of $7.838 billion ¹ in 2025, and Leqvio, with net sales of $754 million ² in 2025. The Immunology segment includes Cosentyx, with net sales of $6.089 billion ³ in 2025, and Ilaris, with net sales of $1.393 billion ⁴ in 2025. The Neuroscience segment includes Kesimpta, with net sales of $3.242 billion ⁵ in 2025, and Zolgensma, with net sales of $1.003 billion ⁶ in 2025. The Oncology segment includes Kisqali, with net sales of $3.017 billion ⁷ in 2025, and Pluvicto, with net sales of $1.482 billion ⁸ in 2025. The Established Brands segment includes Sandostatin, with net sales of $1.581 billion ⁹ in 2025, and the Exforge Group, with net sales of $1.071 billion ¹⁰ in 2025.

During the period, Novartis completed several significant acquisitions. In 2024, the company acquired MorphoSys AG for a total consideration of $2.9 billion ¹¹, Mariana Oncology Inc. for $1.0 billion ¹², and Kate Therapeutics Inc. for $1.1 billion ¹³. In 2025, the company acquired Anthos Therapeutics Inc. for $0.9 billion ¹⁴, Regulus Therapeutics Inc. for $0.8 billion ¹⁵, and Tourmaline Bio Inc. for $0.6 billion ¹⁶. The company also completed the spin-off of its Sandoz business on October 4, 2023, which was accounted for as a discontinued operation. In 2025, the company repurchased 30,000,000 ¹⁷ shares of its own equity for $3.0 billion ¹⁸ and paid dividends of $7.9 billion ¹⁹ to its shareholders.

In 2025, total net sales from continuing operations were $50.318 billion ²⁰, compared to $47.017 billion ²¹ in 2024, representing an increase of 7% ²². Core operating income was $19.5 billion ²³ in 2025, compared to $17.9 billion ²⁴ in 2024. Net income from continuing operations was $11.9 billion ²⁵ in 2025, compared to $11.8 billion ²⁶ in 2024. Free cash flow from continuing operations was $14.5 billion ²⁷ in 2025, compared to $13.5 billion ²⁸ in 2024.

A key growth vector is the continued expansion of Entresto, which achieved net sales of $7.838 billion ²⁹ in 2025, and the launch and uptake of Vanrafia, a new product in the Cardiovascular, Renal and Metabolic segment. Another major growth vector is the Oncology portfolio, driven by the strong performance of Kisqali, which generated net sales of $3.017 billion ³⁰ in 2025, and the radioligand therapies Pluvicto and Lutathera, with net sales of $1.482 billion ³¹ and $618 million ³² respectively. The company is also investing in its pipeline, including the acquisition of Anthos Therapeutics Inc. for $0.9 billion ³³ to bolster its cardiovascular pipeline.

Another growth vector is the Immunology and Neuroscience franchises. Cosentyx remains a key driver with net sales of $6.089 billion ³⁴ in 2025, and the company is pursuing label expansions. Kesimpta, in the Neuroscience segment, grew to net sales of $3.242 billion ³⁵ in 2025. The company is also investing in new technologies and therapeutic areas through business development, including the acquisitions of Kate Therapeutics Inc. for $1.1 billion ³⁶ and Tourmaline Bio Inc. for $0.6 billion ³⁷ to access novel gene therapies and immunology assets.

The filing does not provide a specific margin and cost outlook with exact figures for future periods.

The filing does not provide a specific operational outlook with exact figures for future periods.The filing does not explicitly discuss specific headwinds and constraints in a forward-looking context with quantified figures.

Management's message emphasizes the successful transformation of Novartis into a pure-play innovative medicines company following the Sandoz spin-off. Key strategic priorities include driving growth from its key brands, advancing its pipeline through internal research and external business development, and delivering strong financial performance. The tone is confident, highlighting the 7% ⁴² growth in net sales and the generation of $14.5 billion ⁴³ in free cash flow from continuing operations in 2025. Management underscores a focus on innovation and shareholder value creation.

For the fiscal year 2025, total net sales from continuing operations were $50.318 billion ⁴⁴, compared to $47.017 billion ⁴⁵ in 2024. Net income from continuing operations was $11.9 billion ⁴⁶ in 2025, compared to $11.8 billion ⁴⁷ in 2024. Diluted earnings per share from continuing operations were $5.88 ⁴⁸ in 2025, compared to $5.74 ⁴⁹ in 2024. Core operating income from continuing operations was $19.5 billion ⁵⁰ in 2025, compared to $17.9 billion ⁵¹ in 2024. Free cash flow from continuing operations was $14.5 billion ⁵² in 2025, compared to $13.5 billion ⁵³ in 2024. The company reported net debt of $12.9 billion ⁵⁴ as of December 31, 2025. In 2025, the company recognized impairment charges of $1.2 billion ⁵⁵ related to intangible assets, which reduced reported net income. By segment, the Oncology segment reported net sales of $15.6 billion ⁵⁶ in 2025, while the Immunology segment reported net sales of $8.5 billion ⁵⁷.

A material risk is the loss of patent protection for key products, leading to generic competition and significant revenue declines. For example, Entresto, which generated $7.838 billion ³⁸ in net sales in 2025, faces patent expirations in the coming years. Another significant risk is the company's substantial exposure to pricing and access pressures from government healthcare programs and private payers, particularly in the U.S. market, which accounted for a large portion of sales. The company also faces risks related to the successful development and commercialization of its pipeline, including the risk of clinical trial failures or regulatory setbacks. The acquisitions of MorphoSys AG for $2.9 billion ³⁹, Mariana Oncology Inc. for $1.0 billion ⁴⁰, and Kate Therapeutics Inc. for $1.1 billion ⁴¹ expose the company to integration risks and the risk that the acquired assets may not achieve their expected commercial potential. Additionally, the company is subject to extensive and complex regulations, including pricing and reimbursement controls, which could materially impact its financial results.